SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 3, 2024 (the “Grant Date”), ORIC granted a total of 173,200 non-qualified stock options and 28,900 restricted stock units to three new non-executive employees who began their employment with ORIC in August 2024. These inducement grants were ...

财务状况 - 公司在2024年上半年的净亏损为5,697万美元[76] - 公司通过私募配股等方式筹集了2.25亿美元资金[81] - 公司预计现有现金和投资将可支持运营至2026年底[82] - 未来资金需求取决于多方面因素,如产品研发进度、监管审批、商业化等[83,84] - 经营活动现金流出增加,主要由于净亏损和营运资金变动[85,86] - 投资活动现金流出增加,主要用于购买投资[87] - 筹资活动现金流入增加,主要来自私募配股[88] 研发进展 - 研发费用增加主要是由于ORIC-114和ORIC-944项目的推进[77] - 公司正在评估ORIC-533与其他免疫疗法的联合开发[68] - 公司正在进行ORIC-944与其他前列腺癌药物的联合临床试验[68] - ORIC-114在第1b期临床试验中显示了体内和脑内的疗效[68] - 公司计划在2025年上半年公布ORIC-114的更新临床数据[68] - 公司正在优化ORIC-114的剂量以确定最终的推荐剂量[68] - 研发费用预计将大幅增加,以支持产品候选药物的开发[79] 商业化合作 - 公司正在积极拓展商业化合作以推进产品开发[68] 会计政策变更 - 公司采用新会计准则,未选择延长过渡期[89,90] 风险因素 - 公司面临利率风险,但目前影响较小[91]

财务状况 - 现金、现金等价物和投资总额为3.085亿美元，预计可为公司运营计划提供资金支持至2026年底[11] 研发费用 - 研发费用同比增加1020万美元，主要由于产品候选药物和发现项目的外部费用增加以及人员成本上升[12] 一般及行政费用 - 一般及行政费用同比增加90万美元，主要由于人员成本上升[13] 临床试验进展 - 启动了ORIC-944与NUBEQA®和ERLEADA®联合用药的I期临床试验[2,3,8] - 完成了ORIC-114 I期临床试验剂量递增部分,选定了两个推荐二期试验剂量[7] - 在ORIC-114 I期临床试验中首次给药三个扩展队列患者,包括EGFR外显子20插入突变、HER2外显子20插入突变和EGFR非典型突变的非小细胞肺癌[7] - 启动了评估ORIC-114用于一线EGFR外显子20插入突变非小细胞肺癌患者的延伸队列[7] 团队建设 - 任命Keith Lui为商业和医疗事务高级副总裁,扩大了领导团队[4,10]

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 3, 2024 (the "Grant Date"), ORIC granted a total of 30,000 non-qualified stock options and 4,800 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2024. These inducement grants were granted pu ...

ORIC Pharmaceuticals, Inc. (ORIC) announced that it has collaborated with pharma giants Bayer (BAYRY) and Janssen Research & Development, LLC, a Johnson & Johnson (JNJ) company, to support its ongoing study evaluating pipeline candidate ORIC-944.ORIC will evaluate ORIC-944 in combination with Bayer’s Nubeqa (darolutamide), an androgen receptor (AR) inhibitor, and Johnson & Johnson’s AR inhibitor Erleada (apalutamide).ORIC-944 is a potent and selective allosteric inhibitor of polycomb repressive complex 2 (P ...

ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC ORIC entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, to ...

ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC ORIC entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, t ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 3, 2024 (the “Grant Date”), ORIC granted a total of 30,000 non-qualified stock options and 4,800 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2024. These inducement grants were granted pu ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in June: Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 5, 2024, at 10:30 a.m. ET. Goldman Sachs 45th Annual Global Healthcare Conference – Pa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1787157 ( ...